A Phase 1/2 interventional study of BMS-813160 and Nivolumab in Colorectal Cancer and Pancreatic Cancer, sponsored by Bristol-Myers Squibb. Completed at 40 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-09.
Sponsored by Bristol-Myers Squibb · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Colorectal Neoplasms by Bristol-Myers Squibb — 4 open to participants now, 9 under way, 3 of them phase 3. Colorectal Neoplasms · Bristol-Myers Squibb.
Among the 29 studies in Colorectal Neoplasms by Bristol-Myers Squibb, this one is the 9th largest by enrollment of the 27 interventional ones that give a count, is the only one that started in 2017, is one of 10 in phase 1/2, and was the 12th registered.
6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →4 of the 29 studies in Colorectal Neoplasms by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in United States, Argentina, Australia and 22 more countries
Ages 18+
Bristol-Myers Squibb · Sites in United States, Canada, Spain
Ages 18+
Bristol-Myers Squibb · Sites in United States, Australia, Canada
Ages 18+
Bristol-Myers Squibb · Sites in United States, Canada
Ages 18+
By country, each count listing its studies:
Of the 1,181 Colorectal Neoplasms studies recruiting now, 764 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 17 · Phase 3 5
First in 2002; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 332 is above the median of 76 across 4,802 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 171 across the 27 interventional studies, 124 across the 1 observational. Of the 20 that completed or were terminated, 9 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
2 of the studies in Colorectal Neoplasms by Bristol-Myers Squibb that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06544655Bristol-Myers SquibbA Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors | 2027-10-14 |
| NCT06764771Bristol-Myers SquibbA Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors | 2027-10-15 |
Add all 2 to your calendar (.ics) → With an account.
Among the 29 studies in Colorectal Neoplasms by Bristol-Myers Squibb, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety profile, tolerability, drug levels, drug effects, and preliminary efficacy of BMS-813160 alone or in combination with either chemotherapy or nivolumab or chemotherapy plus nivolumab in participants with metastatic colorectal and pancreatic cancers.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FOLFIRI: FOL (folinic acid \[leucovorin\]) F (fluorouracil \[5-fluorouracil\]) IRI (irinotecan \[CAMPTOSAR\])
Drug: BMS-813160 · Drug: 5-fluorouracil (5-FU) · Drug: Leucovorin · Drug: Irinotecan
Drug: BMS-813160 · Drug: Nab-paclitaxel · Drug: Gemcitabine
2L: Second-line 2/3L: Second/third-line MSS: Microsatellite stable
Drug: BMS-813160 · Biological: Nivolumab
Drug: BMS-813160 · Drug: 5-fluorouracil (5-FU) · Drug: Leucovorin · Drug: Irinotecan
Drug: BMS-813160 · Drug: 5-fluorouracil (5-FU) · Drug: Leucovorin · Drug: Irinotecan
Drug: 5-fluorouracil (5-FU) · Drug: Leucovorin · Drug: Irinotecan
Drug: BMS-813160 · Drug: Nab-paclitaxel · Drug: Gemcitabine
Drug: BMS-813160 · Biological: Nivolumab · Drug: Nab-paclitaxel · Drug: Gemcitabine
Drug: Nab-paclitaxel · Drug: Gemcitabine
Drug: BMS-813160 · Biological: Nivolumab
Drug: BMS-813160 · Biological: Nivolumab
Drug: BMS-813160
Drug: BMS-813160
Specified dose on specified days
Specified dose on specified days
Also known as: Opdivo, BMS-936558
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Number of Participants Experiencing Adverse Events (AEs)
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Adverse events are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal.
Time frame: From first dose up to 100 days post last dose, up to approximately 3 years
Number of Participants Experiencing Serious Adverse Events (SAEs)
A Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening (defined as an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe), requires inpatient hospitalization or causes prolongation of existing hospitalization.
Time frame: From first dose up to 100 days post last dose, up to approximately 3 years
Number of Participants Experiencing Dose-Limiting Toxicities (DLTs)
Dose-limiting toxicities (DLTs) are severe adverse effects (AEs) that are attributed to BMS-813160 or the combination regimen and define the maximum tolerated dose of a medicine. DLTs will be defined based on the incidence, duration and grade of AEs for which no alternate cause can be identified. AEs will be evaluated according to the NCI CTCAE v4.03. The incidence of DLT(s) during the first 6 weeks of treatment in Part 1 (the DLT evaluation period) and 4 weeks for Part 2 will be used.
Time frame: From first dose up to 100 days post last dose, up to approximately 3 years
Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation
An Adverse Event (AE) leading to discontinuation is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment that leads to the discontinuation of study treatment. Adverse events are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal.
Time frame: From first dose up to 100 days post last dose, up to approximately 3 years
Number of Participants Who Died
The number of participants who died within 100 days after receiving their last dose
Time frame: From first dose up to 100 days post last dose, up to approximately 3 years
Number of Participants Experiencing Laboratory Abnormalities
The number of participants experiencing laboratory abnormalities in pre-specified selected parameters during the treatment period per CTCAE (Version 4). Laboratory abnormalities are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal.
Time frame: From first dose up to 100 days post last dose, up to approximately 3 years
Vital Signs
Vital sign measurements at baseline and at the end of treatment. Baseline evaluations will be defined as evaluations with a date on or prior to the day of first dose of study treatment.
Time frame: From first dose to 100 days post last dose, up to approximately 3 years
Number of Participants With Out-of-Range Electrocardiograms (ECG)
The number of participants with ECG measurements outside of the range pre-specified in the protocol.
Time frame: From baseline up to 100 days post last dose
Percent Change in Regulatory T Cells (Treg) in Tumor Samples
The percent change in Regulatory T Cells (Treg) were taken at prespecified timepoints. Baseline is defined as the last non-missing value prior to the first dosing.
Time frame: From first dose up to prespecified timepoints listed below (C0D7; C0D14; C1D1; C1D15; C1D16; C1D28; C2D1)
Percent Change in Tumor-Associated Macrophages (TAMs) in Tumor Samples
The percent change in Tumor-Associated Macrophages (TAMs) were taken at prespecified timepoints. Baseline is defined as the last non-missing value prior to the first dosing.
Time frame: From first dose up to prespecified timepoints listed below (C0D7; C0D14; C1D1; C1D15; C1D16; C1D28; C2D1)
Objective Response Rate (ORR)
Objective Response Rate (ORR) as determined by Investigator was defined as the number of participants with a best overall response of confirmed Complete Response (CR) or Partial Response (PR) (per RECIST 1.1 criteria) divided by the number of all treated participants. Progression is defined as at least 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 mm. RECIST 1.1 = Response Evaluation Criteria in Solid Tumors. Complete response (CR)= Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial response (PR)= At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: From first dose until disease progression, or the last response recorded (up to approximately 5 years)
Duration of Response (DoR)
Duration of Response (DOR), computed for all treated participants with a best overall response (BOR) of complete response (CR) or partial response (PR), is defined as the time between the date of first response (CR or PR) and the date of first documented disease progression as determined by RECIST 1.1 or death due to any cause, whichever occurs first, ie., DOR = disease progression date/death date -first response date + 1. For participants who remain alive and have not progressed, DOR will be censored on the date of their last tumor assessment. CR= Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR= At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: From first dose up to date of disease progression or death, whichever occurs first (up to approximately 5 years)
Progression Free Survival (PFS) Rate at 24 Weeks
PFS rate is defined as the proportion of participants who were progression free at Week 24. PFS is defined as the time from first dose to the date of first objectively documented disease progression or death due to any cause, whichever occurs first. Progression is defined at least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 mm. Complete response (CR)= Disappearance of all target lesions. Pathological lymph nodes must have short axis reduction to \< 10 mm. Partial response (PR)= At least 30% decrease in sum of diameters of target lesions. Participants who died w/o prior progression were considered progressed on death date. Those alive and not progressed were censored on the last tumor assessment date. Those who started subsequent therapy without reported progression were censored at last tumor assessment prior to subsequent therapy. Those without post-baseline tumor assessment and alive were censored at first dose.
Time frame: From first dose up to Week 24
Maximim Concentration (Cmax)
Cmax is defined as the maximum plasma concentration of the analytes at the prespecified timepoints.
Time frame: From first dose up to the prespecified timepoints, C0D1, C0D14, and C2D1
Time to Maximum Concentration (Tmax)
Tmax is defined as the time in hours of the maximum observed plasma concentration
Time frame: From first dose up to the prespecified timpoints, C0D1, C0D14, AND C2D1
Trough Observed Plasma Concentration (Ctrough)
Ctrough is defined as the concentration reached by a drug immediately before the next dose is administered
Time frame: From first dose up to prespecified timepoints, C0D1, C5D1, C0D1, C1D15, C5D1
Area Under Curve (AUC) 0-8
Area Under Curve (AUC) is defined as the area under the plot of plasma concentration of a drug versus time after dosage measured at 8 hours post-dose
Time frame: From first dose up to prespecified timepoints- C0D1, C2D1
Area Under Curve (AUC) 0-24
Area Under Curve (AUC) is defined as the area under the plot of plasma concentration of a drug versus time after dosage measured at 8 hours post-dose
Time frame: From first dose up to prespecified timepoints-C0D1, C2D1
Apparent Total Body Clearance (CLT/F)
The total body clearance (CLT/F) is defined as the volume of plasma completely cleared of drug per unit time
Time frame: From first dose up to prespecified timepoints-C0D1, C2D14
Renal Clearance (CLR)
Renal clearance is defined as the rate at which the analytes were removed from the plasma by the kidneys.
Time frame: From first dose up to prespecified timepoints-C0D1, C0D14
Number of Participants Who Were Anti-Drug Antibody (ADA) Positive
The number of participants who are anti-drug antibody positive. ADA-positive participant is a participant with at least 1 ADA-positive sample relative to baseline after initiation of the treatment. ADA-positive sample is in a participant who is baseline ADA negative or with an ADA titer to be at least 4-fold or greater than baseline positive titer.
Time frame: From first dose up to prespecified timepoints-C1D1, C1D15, C2D1, C3D1, C5D1, C9D1
| Milestone | Part 1-Arm A-Cohort 1: 1L CRC/BMS300BID + FOLFIRI | Part 1-Arm A-Cohort 2: 1L CRC/BMS600QD + FOLFIRI | Part 1-Arm B-Cohort 1: 1L PC/BMS300BID + GEM/NAB | Part 1-Arm B-Cohort 2: 1L PC/BMS600QD + GEM/NAB | Part 1-Arm C-Cohort 1: 2/3L CRC MSS/BMS300BID + NIVO | Part 1-Arm C-Cohort 2: 2/3L CRC MSS/BMS600QD + NIVO | Part 1-Arm C-Cohort 3: 2/3L CRC MSS/BMS300QD + NIVO | Part 1-Arm C-Cohort 4: 2/3L CRC MSS/BMS150QD + NIVO | Part 1-Arm C-Cohort 5: 2L PC/BMS300BID + NIVO | Part 1-Arm C-Cohort 6: 2L PC/BMS600QD + NIVO | Part 2-Arm A-Cohort 1a: 2L CRC/BMS300BID + FOLFIRI | Part 2-Arm A-Cohort 1b: 2L CRC/BMS150QD + FOLFIRI | Part 2-Arm A-Cohort 1C: 2L CRC/FOLFIRI | Part 2-Arm B-Cohort 3a: 1L PC/BMS300BID + GEM/NAB | Part 2-Arm B-Cohort 3b: 1L PC/BMS300BID + GEM/NAB + NIVO | Part 2-Arm B-Cohort 3C: 1L PC/GEM/NAB | Part 2-Arm C-Cohort 4: 2L PC/BMS300BID + NIVO | Part 2-Arm C-Cohort 5: 2/3L CRC MSS /BMS300BID + NIVO |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 10 | 8 | 10 | 11 | 8 | 7 | 7 | 11 | 1 | 2 | 32 | 32 | 26 | 35 | 35 | 32 | 24 | 24 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 10 | 8 | 10 | 11 | 8 | 7 | 7 | 11 | 1 | 2 | 32 | 32 | 26 | 35 | 35 | 32 | 24 | 24 |
| Withdrew: Death | 6 | 6 | 8 | 8 | 6 | 6 | 6 | 7 | 1 | 2 | 26 | 28 | 10 | 33 | 34 | 26 | 20 | 18 |
| Withdrew: Other reasons | 2 | 2 | 0 | 1 | 0 | 0 | 0 | 2 | 0 | 0 | 4 | 2 | 2 | 0 | 0 | 1 | 0 | 2 |
| Withdrew: Lost to follow-up | 2 | 0 | 0 | 1 | 1 | 1 | 0 | 2 | 0 | 0 | 2 | 0 | 2 | 2 | 0 | 0 | 2 | 2 |
| Withdrew: Withdrawal by subject | 0 | 0 | 2 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 2 | 3 | 0 | 1 | 5 | 2 | 2 |
| Withdrew: Moved to crossover treatment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part 1-Arm A-Cohort 1: 1L CRC/BMS300BID + FOLFIRI | Part 1-Arm A-Cohort 2: 1L CRC/BMS600QD + FOLFIRI | Part 1-Arm B-Cohort 1: 1L PC/BMS300BID + GEM/NAB | Part 1-Arm B-Cohort 2: 1L PC/BMS600QD + GEM/NAB | Part 1-Arm C-Cohort 1: 2/3L CRC MSS/BMS300BID + NIVO | Part 1-Arm C-Cohort 2: 2/3L CRC MSS/BMS600QD + NIVO | Part 1-Arm C-Cohort 3: 2/3L CRC MSS/BMS300QD + NIVO | Part 1-Arm C-Cohort 4: 2/3L CRC MSS/BMS150QD + NIVO | Part 1-Arm C-Cohort 5: 2L PC/BMS300BID + NIVO | Part 1-Arm C-Cohort 6: 2L PC/BMS600QD + NIVO | Part 2-Arm A-Cohort 1a: 2L CRC/BMS300BID + FOLFIRI | Part 2-Arm A-Cohort 1b: 2L CRC/BMS150QD + FOLFIRI | Part 2-Arm A-Cohort 1C: 2L CRC/FOLFIRI | Part 2-Arm B-Cohort 3a: 1L PC/BMS300BID + GEM/NAB | Part 2-Arm B-Cohort 3b: 1L PC/BMS300BID + GEM/NAB + NIVO | Part 2-Arm B-Cohort 3C: 1L PC/GEM/NAB | Part 2-Arm C-Cohort 4: 2L PC/BMS300BID + NIVO | Part 2-Arm C-Cohort 5: 2/3L CRC MSS /BMS300BID + NIVO |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9 |
| Withdrew: Other reasons | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7 |
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Adverse events are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal.
| Participants | Part 1-Arm A-Cohort 1: 1L CRC/BMS300BID + FOLFIRI | Part 1-Arm A-Cohort 2: 1L CRC/BMS600QD + FOLFIRI | Part 1-Arm B-Cohort 1: 1L PC/BMS300BID + GEM/NAB | Part 1-Arm B-Cohort 2: 1L PC/BMS600QD + GEM/NAB | Part 1-Arm C-Cohort 1: 2/3L CRC MSS/BMS300BID + NIVO | Part 1-Arm C-Cohort 2: 2/3L CRC MSS/BMS600QD + NIVO | Part 1-Arm C-Cohort 3: 2/3L CRC MSS/BMS300QD + NIVO | Part 1-Arm C-Cohort 4: 2/3L CRC MSS/BMS150QD + NIVO | Part 1-Arm C-Cohort 5: 2L PC/BMS300BID + NIVO | Part 1-Arm C-Cohort 6: 2L PC/BMS600QD + NIVO | Part 2-Arm A-Cohort 1a: 2L CRC/BMS300BID + FOLFIRI | Part 2-Arm A-Cohort 1b: 2L CRC/BMS150QD + FOLFIRI | Part 2-Arm A-Cohort 1C: 2L CRC/FOLFIRI | Part 2-Arm B-Cohort 3a: 1L PC/BMS300BID + GEM/NAB | Part 2-Arm B-Cohort 3b: 1L PC/BMS300BID + GEM/NAB + NIVO | Part 2-Arm B-Cohort 3C: 1L PC/GEM/NAB | Part 2-Arm C-Cohort 4: 2L PC/BMS300BID + NIVO | Part 2-Arm C-Cohort 5: 2/3L CRC MSS /BMS300BID + NIVO |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants Experiencing Adverse Events (AEs) | 10 | 8 | 10 | 11 | 8 | 7 | 7 | 11 | 1 | 2 | 32 | 32 | 25 | 35 | 35 | 31 | 23 | 32 |
A Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening (defined as an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe), requires inpatient hospitalization or causes prolongation of existing hospitalization.
| Participants | Part 1-Arm A-Cohort 1: 1L CRC/BMS300BID + FOLFIRI | Part 1-Arm A-Cohort 2: 1L CRC/BMS600QD + FOLFIRI | Part 1-Arm B-Cohort 1: 1L PC/BMS300BID + GEM/NAB | Part 1-Arm B-Cohort 2: 1L PC/BMS600QD + GEM/NAB | Part 1-Arm C-Cohort 1: 2/3L CRC MSS/BMS300BID + NIVO | Part 1-Arm C-Cohort 2: 2/3L CRC MSS/BMS600QD + NIVO | Part 1-Arm C-Cohort 3: 2/3L CRC MSS/BMS300QD + NIVO | Part 1-Arm C-Cohort 4: 2/3L CRC MSS/BMS150QD + NIVO | Part 1-Arm C-Cohort 5: 2L PC/BMS300BID + NIVO | Part 1-Arm C-Cohort 6: 2L PC/BMS600QD + NIVO | Part 2-Arm A-Cohort 1a: 2L CRC/BMS300BID + FOLFIRI | Part 2-Arm A-Cohort 1b: 2L CRC/BMS150QD + FOLFIRI | Part 2-Arm A-Cohort 1C: 2L CRC/FOLFIRI | Part 2-Arm B-Cohort 3a: 1L PC/BMS300BID + GEM/NAB | Part 2-Arm B-Cohort 3b: 1L PC/BMS300BID + GEM/NAB + NIVO | Part 2-Arm B-Cohort 3C: 1L PC/GEM/NAB | Part 2-Arm C-Cohort 4: 2L PC/BMS300BID + NIVO | Part 2-Arm C-Cohort 5: 2/3L CRC MSS /BMS300BID + NIVO |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants Experiencing Serious Adverse Events (SAEs) | 5 | 5 | 5 | 7 | 5 | 6 | 6 | 6 | 1 | 2 | 12 | 12 | 6 | 24 | 22 | 15 | 17 | 19 |
Dose-limiting toxicities (DLTs) are severe adverse effects (AEs) that are attributed to BMS-813160 or the combination regimen and define the maximum tolerated dose of a medicine. DLTs will be defined based on the incidence, duration and grade of AEs for which no alternate cause can be identified. AEs will be evaluated according to the NCI CTCAE v4.03. The incidence of DLT(s) during the first 6 weeks of treatment in Part 1 (the DLT evaluation period) and 4 weeks for Part 2 will be used.
| Participants | Part 1-Arm A-Cohort 1: 1L CRC/BMS300BID + FOLFIRI | Part 1-Arm A-Cohort 2: 1L CRC/BMS600QD + FOLFIRI | Part 1-Arm B-Cohort 1: 1L PC/BMS300BID + GEM/NAB | Part 1-Arm B-Cohort 2: 1L PC/BMS600QD + GEM/NAB | Part 1-Arm C-Cohort 1: 2/3L CRC MSS/BMS300BID + NIVO | Part 1-Arm C-Cohort 2: 2/3L CRC MSS/BMS600QD + NIVO | Part 1-Arm C-Cohort 3: 2/3L CRC MSS/BMS300QD + NIVO | Part 1-Arm C-Cohort 4: 2/3L CRC MSS/BMS150QD + NIVO | Part 1-Arm C-Cohort 5: 2L PC/BMS300BID + NIVO | Part 1-Arm C-Cohort 6: 2L PC/BMS600QD + NIVO | Part 2-Arm A-Cohort 1a: 2L CRC/BMS300BID + FOLFIRI | Part 2-Arm A-Cohort 1b: 2L CRC/BMS150QD + FOLFIRI | Part 2-Arm A-Cohort 1C: 2L CRC/FOLFIRI | Part 2-Arm B-Cohort 3a: 1L PC/BMS300BID + GEM/NAB | Part 2-Arm B-Cohort 3b: 1L PC/BMS300BID + GEM/NAB + NIVO | Part 2-Arm B-Cohort 3C: 1L PC/GEM/NAB | Part 2-Arm C-Cohort 4: 2L PC/BMS300BID + NIVO | Part 2-Arm C-Cohort 5: 2/3L CRC MSS /BMS300BID + NIVO |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) | 0 | 0 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
An Adverse Event (AE) leading to discontinuation is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment that leads to the discontinuation of study treatment. Adverse events are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal.
| Participants | Part 1-Arm A-Cohort 1: 1L CRC/BMS300BID + FOLFIRI | Part 1-Arm A-Cohort 2: 1L CRC/BMS600QD + FOLFIRI | Part 1-Arm B-Cohort 1: 1L PC/BMS300BID + GEM/NAB | Part 1-Arm B-Cohort 2: 1L PC/BMS600QD + GEM/NAB | Part 1-Arm C-Cohort 1: 2/3L CRC MSS/BMS300BID + NIVO | Part 1-Arm C-Cohort 2: 2/3L CRC MSS/BMS600QD + NIVO | Part 1-Arm C-Cohort 3: 2/3L CRC MSS/BMS300QD + NIVO | Part 1-Arm C-Cohort 4: 2/3L CRC MSS/BMS150QD + NIVO | Part 1-Arm C-Cohort 5: 2L PC/BMS300BID + NIVO | Part 1-Arm C-Cohort 6: 2L PC/BMS600QD + NIVO | Part 2-Arm A-Cohort 1a: 2L CRC/BMS300BID + FOLFIRI | Part 2-Arm A-Cohort 1b: 2L CRC/BMS150QD + FOLFIRI | Part 2-Arm A-Cohort 1C: 2L CRC/FOLFIRI | Part 2-Arm B-Cohort 3a: 1L PC/BMS300BID + GEM/NAB | Part 2-Arm B-Cohort 3b: 1L PC/BMS300BID + GEM/NAB + NIVO | Part 2-Arm B-Cohort 3C: 1L PC/GEM/NAB | Part 2-Arm C-Cohort 4: 2L PC/BMS300BID + NIVO | Part 2-Arm C-Cohort 5: 2/3L CRC MSS /BMS300BID + NIVO |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation | 2 | 0 | 1 | 6 | 0 | 1 | 0 | 1 | 0 | 1 | 10 | 6 | 2 | 12 | 8 | 3 | 4 | 2 |
The number of participants who died within 100 days after receiving their last dose
| Participants | Part 1-Arm A-Cohort 1: 1L CRC/BMS300BID + FOLFIRI | Part 1-Arm A-Cohort 2: 1L CRC/BMS600QD + FOLFIRI | Part 1-Arm B-Cohort 1: 1L PC/BMS300BID + GEM/NAB | Part 1-Arm B-Cohort 2: 1L PC/BMS600QD + GEM/NAB | Part 1-Arm C-Cohort 1: 2/3L CRC MSS/BMS300BID + NIVO | Part 1-Arm C-Cohort 2: 2/3L CRC MSS/BMS600QD + NIVO | Part 1-Arm C-Cohort 3: 2/3L CRC MSS/BMS300QD + NIVO | Part 1-Arm C-Cohort 4: 2/3L CRC MSS/BMS150QD + NIVO | Part 1-Arm C-Cohort 5: 2L PC/BMS300BID + NIVO | Part 1-Arm C-Cohort 6: 2L PC/BMS600QD + NIVO | Part 2-Arm A-Cohort 1a: 2L CRC/BMS300BID + FOLFIRI | Part 2-Arm A-Cohort 1b: 2L CRC/BMS150QD + FOLFIRI | Part 2-Arm A-Cohort 1C: 2L CRC/FOLFIRI | Part 2-Arm B-Cohort 3a: 1L PC/BMS300BID + GEM/NAB | Part 2-Arm B-Cohort 3b: 1L PC/BMS300BID + GEM/NAB + NIVO | Part 2-Arm B-Cohort 3C: 1L PC/GEM/NAB | Part 2-Arm C-Cohort 4: 2L PC/BMS300BID + NIVO | Part 2-Arm C-Cohort 5: 2/3L CRC MSS /BMS300BID + NIVO |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants Who Died | 6 | 6 | 8 | 8 | 6 | 6 | 6 | 7 | 1 | 2 | 26 | 28 | 17 | 33 | 34 | 26 | 20 | 25 |
The number of participants experiencing laboratory abnormalities in pre-specified selected parameters during the treatment period per CTCAE (Version 4). Laboratory abnormalities are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal.
| Participants | Part 1-Arm A-Cohort 1: 1L CRC/BMS300BID + FOLFIRI | Part 1-Arm A-Cohort 2: 1L CRC/BMS600QD + FOLFIRI | Part 1-Arm B-Cohort 1: 1L PC/BMS300BID + GEM/NAB | Part 1-Arm B-Cohort 2: 1L PC/BMS600QD + GEM/NAB | Part 1-Arm C-Cohort 1: 2/3L CRC MSS/BMS300BID + NIVO | Part 1-Arm C-Cohort 2: 2/3L CRC MSS/BMS600QD + NIVO | Part 1-Arm C-Cohort 3: 2/3L CRC MSS/BMS300QD + NIVO | Part 1-Arm C-Cohort 4: 2/3L CRC MSS/BMS150QD + NIVO | Part 1-Arm C-Cohort 5: 2L PC/BMS300BID + NIVO | Part 1-Arm C-Cohort 6: 2L PC/BMS600QD + NIVO | Part 2-Arm A-Cohort 1a: 2L CRC/BMS300BID + FOLFIRI | Part 2-Arm A-Cohort 1b: 2L CRC/BMS150QD + FOLFIRI | Part 2-Arm A-Cohort 1C: 2L CRC/FOLFIRI | Part 2-Arm B-Cohort 3a: 1L PC/BMS300BID + GEM/NAB | Part 2-Arm B-Cohort 3b: 1L PC/BMS300BID + GEM/NAB + NIVO | Part 2-Arm B-Cohort 3C: 1L PC/GEM/NAB | Part 2-Arm C-Cohort 4: 2L PC/BMS300BID + NIVO | Part 2-Arm C-Cohort 5: 2/3L CRC MSS /BMS300BID + NIVO |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALANINE AMINOTRANSFERASE (ALT), LOCAL LAB (U/L) - Abnormal High | 2 | 4 | 5 | 7 | 2 | 1 | 3 | 6 | 1 | 1 | 15 | 9 | 10 | 24 | 28 | 24 | 10 | 13 |
| ASPARTATE AMINOTRANSFERASE (AST), LOCAL LAB (U/L) - Abnormal High | 2 | 4 | 5 | 7 | 3 | 3 | 5 | 5 | 1 | 1 | 15 | 12 | 9 | 21 | 26 | 24 | 12 | 19 |
| Total Bilirubin (UMOL/L) - Abnormal High | 2 | 4 | 5 | 2 | 1 | 1 | 4 | 3 | 1 | 1 | 5 | 5 | 2 | 8 | 7 | 5 | 6 | 7 |
| Neutrophils (Absolute) (10^9/L) - Abnormal Low | 6 | 4 | 5 | 9 | 2 | 1 | 1 | 2 | 0 | 0 | 25 | 20 | 18 | 22 | 25 | 25 | 1 | 4 |
| PLATELET COUNT (10^9/L) - Abnormal Low | 5 | 1 | 5 | 5 | 2 | 1 | 1 | 3 | 0 | 0 | 11 | 15 | 8 | 24 | 28 | 26 | 10 | 5 |
Vital sign measurements at baseline and at the end of treatment. Baseline evaluations will be defined as evaluations with a date on or prior to the day of first dose of study treatment.
| mmHg | Part 1-Arm A-Cohort 1: 1L CRC/BMS300BID + FOLFIRI | Part 1-Arm A-Cohort 2: 1L CRC/BMS600QD + FOLFIRI | Part 1-Arm B-Cohort 1: 1L PC/BMS300BID + GEM/NAB | Part 1-Arm B-Cohort 2: 1L PC/BMS600QD + GEM/NAB | Part 1-Arm C-Cohort 1: 2/3L CRC MSS/BMS300BID + NIVO | Part 1-Arm C-Cohort 2: 2/3L CRC MSS/BMS600QD + NIVO | Part 1-Arm C-Cohort 3: 2/3L CRC MSS/BMS300QD + NIVO | Part 1-Arm C-Cohort 4: 2/3L CRC MSS/BMS150QD + NIVO | Part 1-Arm C-Cohort 5: 2L PC/BMS300BID + NIVO | Part 1-Arm C-Cohort 6: 2L PC/BMS600QD + NIVO | Part 2-Arm A-Cohort 1a: 2L CRC/BMS300BID + FOLFIRI | Part 2-Arm A-Cohort 1b: 2L CRC/BMS150QD + FOLFIRI | Part 2-Arm A-Cohort 1C: 2L CRC/FOLFIRI | Part 2-Arm B-Cohort 3a: 1L PC/BMS300BID + GEM/NAB | Part 2-Arm B-Cohort 3b: 1L PC/BMS300BID + GEM/NAB + NIVO | Part 2-Arm B-Cohort 3C: 1L PC/GEM/NAB | Part 2-Arm C-Cohort 4: 2L PC/BMS300BID + NIVO | Part 2-Arm C-Cohort 5: 2/3L CRC MSS /BMS300BID + NIVO |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Systolic Blood Pressure (mmHg) - End of Treatment | 133.0 ± NA | 129.7 ± 6.7 | 130.2 ± 21.8 | 143.0 ± 34.0 | 114.0 ± 15.0 | 125.0 ± 6.1 | 140.3 ± 18.0 | 124.0 ± 23.7 | 151.0 ± NA | 107.0 ± NA | 126.0 ± 15.9 | 113.0 ± NA | 113.0 ± NA | 123.2 ± 18.8 | 128.9 ± 17.8 | 118.8 ± 15.9 | 112.6 ± 11.6 | 123.1 ± 13.6 |
| Systolic Blood Pressure (mmHg) - Follow-up | 140.0 ± 8.5 | 124.5 ± 2.1 | 100.0 ± NA | 143.0 ± 34.0 | 140.0 ± 8.5 | 108.0 ± NA | 148.0 ± NA | 129.5 ± 29.0 | — | — | 127.9 ± 13.2 | 131.3 ± 20.6 | 113.6 ± 8.1 | 119.2 ± 15.1 | 142.6 ± 16.0 | 108.3 ± 30.1 | 113.0 ± NA | 113.5 ± 6.4 |
| Diastolic Blood Pressure (mmHg) - End of Treatment | 83.0 ± NA | 73.3 ± 7.2 | 75.4 ± 12.4 | 80.8 ± 17.7 | 69.6 ± 9.4 | 86.0 ± 18.2 | 89.7 ± 11.1 | 74.3 ± 11.3 | 86.0 ± NA | 67.0 ± NA | 79.0 ± 11.5 | 74.5 ± 3.5 | 75.0 ± NA | 69.2 ± 8.2 | 74.3 ± 8.6 | 70.2 ± 8.6 | 68.1 ± 6.5 | 74.3 ± 9.7 |
| Diastolic Blood Pressure (mmHg)- Follow-up | 79.0 ± NA | 71.5 ± 14.8 | 59.0 ± NA | — | 85.0 ± 2.8 | 69.0 ± NA | 98.0 ± NA | 72.5 ± 4.9 | — | — | 76.6 ± 14.6 | 76.1 ± 11.0 | 78.2 ± 7.3 | 68.0 ± 9.9 | 70.2 ± 10.5 | 66.7 ± 20.1 | 85.0 ± NA | 69.0 ± 2.8 |
The number of participants with ECG measurements outside of the range pre-specified in the protocol.
| Participants | Part 1-Arm A-Cohort 1: 1L CRC/BMS300BID + FOLFIRI | Part 1-Arm A-Cohort 2: 1L CRC/BMS600QD + FOLFIRI | Part 1-Arm B-Cohort 1: 1L PC/BMS300BID + GEM/NAB | Part 1-Arm B-Cohort 2: 1L PC/BMS600QD + GEM/NAB | Part 1-Arm C-Cohort 1: 2/3L CRC MSS/BMS300BID + NIVO | Part 1-Arm C-Cohort 2: 2/3L CRC MSS/BMS600QD + NIVO | Part 1-Arm C-Cohort 3: 2/3L CRC MSS/BMS300QD + NIVO | Part 1-Arm C-Cohort 4: 2/3L CRC MSS/BMS150QD + NIVO | Part 1-Arm C-Cohort 5: 2L PC/BMS300BID + NIVO | Part 1-Arm C-Cohort 6: 2L PC/BMS600QD + NIVO | Part 2-Arm A-Cohort 1a: 2L CRC/BMS300BID + FOLFIRI | Part 2-Arm A-Cohort 1b: 2L CRC/BMS150QD + FOLFIRI | Part 2-Arm A-Cohort 1C: 2L CRC/FOLFIRI | Part 2-Arm B-Cohort 3a: 1L PC/BMS300BID + GEM/NAB | Part 2-Arm B-Cohort 3b: 1L PC/BMS300BID + GEM/NAB + NIVO | Part 2-Arm B-Cohort 3C: 1L PC/GEM/NAB | Part 2-Arm C-Cohort 4: 2L PC/BMS300BID + NIVO | Part 2-Arm C-Cohort 5: 2/3L CRC MSS /BMS300BID + NIVO |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| QTcF INTERVAL (MSEC) < 450 | 7 | 8 | 10 | 8 | 8 | 7 | 7 | 10 | 1 | 2 | 31 | 27 | 23 | 26 | 30 | 26 | 24 | 31 |
| QTcF INTERVAL (MSEC): 450 <= QTcF < 480 | 3 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 4 | 2 | 6 | 4 | 3 | 0 | 2 |
| 480<=QTcF<500 (MSEC) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| QTcF>= 500 (MSEC) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| QTcB INTERVAL (MSEC) < 450 | 4 | 7 | 8 | 5 | 7 | 3 | 3 | 7 | 1 | 2 | 20 | 21 | 15 | 14 | 17 | 19 | 21 | 15 |
| 450<=QTcB<480 (MSEC) | 5 | 1 | 1 | 3 | 1 | 4 | 3 | 2 | 0 | 0 | 11 | 7 | 10 | 14 | 14 | 8 | 3 | 18 |
| 480<=QTcB<500 (MSEC) | 1 | 0 | 1 | 2 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 3 | 0 | 4 | 3 | 2 | 0 | 0 |
| QTcB>= 500 (MSEC) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 2 | 0 | 0 | 0 | 0 |
The percent change in Regulatory T Cells (Treg) were taken at prespecified timepoints. Baseline is defined as the last non-missing value prior to the first dosing.
| Percent change in Treg | Part 1-Arm A-Cohort 1: 1L CRC/BMS300BID + FOLFIRI | Part 1-Arm A-Cohort 2: 1L CRC/BMS600QD + FOLFIRI | Part 1-Arm B-Cohort 1: 1L PC/BMS300BID + GEM/NAB | Part 1-Arm B-Cohort 2: 1L PC/BMS600QD + GEM/NAB | Part 1-Arm C-Cohort 1: 2/3L CRC MSS/BMS300BID + NIVO | Part 1-Arm C-Cohort 2: 2/3L CRC MSS/BMS600QD + NIVO | Part 1-Arm C-Cohort 3: 2/3L CRC MSS/BMS300QD + NIVO | Part 1-Arm C-Cohort 4: 2/3L CRC MSS/BMS150QD + NIVO | Part 1-Arm C-Cohort 5: 2L PC/BMS300BID + NIVO | Part 1-Arm C-Cohort 6: 2L PC/BMS600QD + NIVO | Part 2-Arm A-Cohort 1a: 2L CRC/BMS300BID + FOLFIRI | Part 2-Arm A-Cohort 1b: 2L CRC/BMS150QD + FOLFIRI | Part 2-Arm A-Cohort 1C: 2L CRC/FOLFIRI | Part 2-Arm B-Cohort 3a: 1L PC/BMS300BID + GEM/NAB | Part 2-Arm B-Cohort 3b: 1L PC/BMS300BID + GEM/NAB + NIVO | Part 2-Arm B-Cohort 3C: 1L PC/GEM/NAB | Part 2-Arm C-Cohort 4: 2L PC/BMS300BID + NIVO | Part 2-Arm C-Cohort 5: 2/3L CRC MSS /BMS300BID + NIVO |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FOXP3 - C0D7 | 26.6 (-67 to 180) | -43.8 (-58 to -15) | -22.9 (-74 to -14) | 156.4 (-12 to 177) | 57.3 (-76 to 116) | -18.4 (-27 to -9) | -92.2 (-94 to 27) | 96.4 (14 to 152) | — | 101.0 (101 to 101) | — | — | — | — | — | — | — | — |
| FOXP3 - C0D14 | 26.5 (-50 to 103) | -19.8 (-78 to 53) | 60.0 (60 to 60) | -41.6 (-67 to -16) | -41 (-41 to -41) | -26.5 (-57 to 249) | 180.2 (-60 to 421) | -3.7 (-9 to 25) | — | — | — | — | — | — | — | — | — | — |
| FOXP3 - C1D1 | — | — | — | — | 34.7 (-58 to 128) | 49 (49 to 49) | 147.4 (20 to 275) | 33.0 (-51 to 338) | — | 31.0 (31 to 31) | — | — | — | — | — | — | — | — |
| FOXP3 - C1D15 | — | — | — | — | -25.9 (-48 to -6) | 14.5 (-90 to 322) | 39.1 (4 to 74) | -33 (-33 to -33) | — | — | — | -39.1 (-46 to -32) | 60 (60 to 60) | 113.6 (-1 to 228) | — | 17.0 (-39 to 73) | -64 (-64 to -64) | — |
| FOXP3 - C1D16 | — | — | — | — | — | — | — | — | — | — | -21 (-21 to -21) | — | — | — | — | — | — | — |
| FOXP3 - C1D28 | — | — | — | — | — | — | — | — | — | — | -7.4 (-26 to 113) | -77.0 (-93 to -61) | 12.0 (-73 to 152) | -36.0 (-77 to -5) | 99.4 (-96 to 2199) | -46.6 (-55 to 551) | 216.7 (98 to 363) | -13.6 (-78 to 149) |
| FOXP3 - C2D1 | — | — | — | — | — | — | — | — | — | — | 305.2 (-73 to 683) | — | — | — | — | 184 (184 to 184) | -2.4 (-37 to 32) | 156.2 (13 to 299) |
The percent change in Tumor-Associated Macrophages (TAMs) were taken at prespecified timepoints. Baseline is defined as the last non-missing value prior to the first dosing.
| Percent change in TAM | Part 1-Arm A-Cohort 1: 1L CRC/BMS300BID + FOLFIRI | Part 1-Arm A-Cohort 2: 1L CRC/BMS600QD + FOLFIRI | Part 1-Arm B-Cohort 1: 1L PC/BMS300BID + GEM/NAB | Part 1-Arm B-Cohort 2: 1L PC/BMS600QD + GEM/NAB | Part 1-Arm C-Cohort 1: 2/3L CRC MSS/BMS300BID + NIVO | Part 1-Arm C-Cohort 2: 2/3L CRC MSS/BMS600QD + NIVO | Part 1-Arm C-Cohort 3: 2/3L CRC MSS/BMS300QD + NIVO | Part 1-Arm C-Cohort 4: 2/3L CRC MSS/BMS150QD + NIVO | Part 1-Arm C-Cohort 5: 2L PC/BMS300BID + NIVO | Part 1-Arm C-Cohort 6: 2L PC/BMS600QD + NIVO | Part 2-Arm A-Cohort 1a: 2L CRC/BMS300BID + FOLFIRI | Part 2-Arm A-Cohort 1b: 2L CRC/BMS150QD + FOLFIRI | Part 2-Arm A-Cohort 1C: 2L CRC/FOLFIRI | Part 2-Arm B-Cohort 3a: 1L PC/BMS300BID + GEM/NAB | Part 2-Arm B-Cohort 3b: 1L PC/BMS300BID + GEM/NAB + NIVO | Part 2-Arm B-Cohort 3C: 1L PC/GEM/NAB | Part 2-Arm C-Cohort 4: 2L PC/BMS300BID + NIVO | Part 2-Arm C-Cohort 5: 2/3L CRC MSS /BMS300BID + NIVO |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CD163 Positive - C0D7 | — | — | — | — | — | — | 13.1 (2 to 808) | -12.7 (-67 to 231) | — | — | — | — | — | — | — | — | — | — |
| CD163 Positive - C0D14 | — | — | — | — | — | — | 95.4 (34 to 157) | 133.6 (0 to 286) | — | — | — | — | — | — | — | — | — | — |
| CD163 Positive - C1D1 | — | — | — | — | — | — | 477.5 (334 to 621) | 22.1 (-28 to 520) | — | — | — | — | — | — | — | — | — | — |
| CD163 Positive - C1D15 | — | — | — | — | — | — | 7.6 (-37 to 53) | -93 (-93 to -93) | — | — | — | 89.8 (35 to 132) | -61 (-61 to -61) | 145.7 (43 to 248) | — | 60.3 (1 to 120) | — | — |
| CD163 Positive - C1D16 | — | — | — | — | — | — | — | — | — | — | 1369 (1369 to 1369) | — | — | — | — | — | — | — |
| CD163 Positive - C1D28 | — | — | — | — | — | — | — | — | — | — | -4.1 (-21 to 1072) | -58.4 (-98 to -19) | 106.3 (-67 to 511) | -14.7 (-57 to 91) | 65.5 (-31 to 666) | 1.0 (-96 to 61) | — | — |
| CD163 Positive - C2D1 | — | — | — | — | — | — | — | — | — | — | -58.3 (-94 to -22) | — | — | — | — | -41.3 (-61 to -33) | — | 39.3 (-1 to 79) |
| CD68 Positive - C0D7 | — | — | — | — | — | — | -70.2 (-91 to 107) | -17.1 (-64 to -2) | — | — | — | — | — | — | — | — | — | — |
| CD68 Positive - C0D14 | — | — | — | — | — | — | 57.7 (-12 to 128) | 7.9 (-8 to 24) | — | — | — | — | — | — | — | — | — | — |
| CD68 Positive - C1D1 | — | — | — | — | — | — | 294.2 (203 to 385) | 17.8 (-39 to 102) | — | — | — | — | — | — | — | — | — | — |
| CD68 Positive - C1D15 | — | — | — | — | — | — | 2.9 (-26 to 185) | -26 (-26 to -26) | — | — | — | -4.0 (-27 to 58) | 81 (81 to 81) | 162.4 (150 to 175) | — | 92.5 (20 to 165) | — | — |
| CD68 Positive - C1D16 | — | — | — | — | — | — | — | — | — | — | 272 (272 to 272) | — | — | — | — | — | — | — |
| CD68 Positive - C1D28 | — | — | — | — | — | — | — | — | — | — | 31.5 (-60 to 296) | -70.7 (-92 to -49) | 96.2 (-50 to 1106) | -38.3 (-88 to 121) | 96.2 (-25 to 179) | -4.3 (-46 to 102) | — | — |
| CD68 Positive - C2D1 | — | — | — | — | — | — | — | — | — | — | -26.9 (-50 to -4) | — | — | — | — | -40.0 (-54 to -33) | — | -66 (-66 to -66) |
Objective Response Rate (ORR) as determined by Investigator was defined as the number of participants with a best overall response of confirmed Complete Response (CR) or Partial Response (PR) (per RECIST 1.1 criteria) divided by the number of all treated participants. Progression is defined as at least 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 mm. RECIST 1.1 = Response Evaluation Criteria in Solid Tumors. Complete response (CR)= Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial response (PR)= At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
| Percent of participants | Part 1-Arm A-Cohort 1: 1L CRC/BMS300BID + FOLFIRI | Part 1-Arm A-Cohort 2: 1L CRC/BMS600QD + FOLFIRI | Part 1-Arm B-Cohort 1: 1L PC/BMS300BID + GEM/NAB | Part 1-Arm B-Cohort 2: 1L PC/BMS600QD + GEM/NAB | Part 1-Arm C-Cohort 1: 2/3L CRC MSS/BMS300BID + NIVO | Part 1-Arm C-Cohort 2: 2/3L CRC MSS/BMS600QD + NIVO | Part 1-Arm C-Cohort 3: 2/3L CRC MSS/BMS300QD + NIVO | Part 1-Arm C-Cohort 4: 2/3L CRC MSS/BMS150QD + NIVO | Part 1-Arm C-Cohort 5: 2L PC/BMS300BID + NIVO | Part 1-Arm C-Cohort 6: 2L PC/BMS600QD + NIVO | Part 2-Arm A-Cohort 1a: 2L CRC/BMS300BID + FOLFIRI | Part 2-Arm A-Cohort 1b: 2L CRC/BMS150QD + FOLFIRI | Part 2-Arm A-Cohort 1C: 2L CRC/FOLFIRI | Part 2-Arm B-Cohort 3a: 1L PC/BMS300BID + GEM/NAB | Part 2-Arm B-Cohort 3b: 1L PC/BMS300BID + GEM/NAB + NIVO | Part 2-Arm B-Cohort 3C: 1L PC/GEM/NAB | Part 2-Arm C-Cohort 4: 2L PC/BMS300BID + NIVO | Part 2-Arm C-Cohort 5: 2/3L CRC MSS /BMS300BID + NIVO |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Objective Response Rate (ORR) | 60.0 (26.2 to 87.8) | 25.0 (3.2 to 65.1) | 0 (0.0 to 30.8) | 18.2 (2.3 to 51.8) | 0 (0.0 to 36.9) | 0 (0.0 to 41.0) | 0 (0.0 to 41.0) | 0 (0.0 to 28.5) | 0 (0.0 to 97.5) | 0 (0.0 to 84.2) | 9.4 (2.0 to 25.0) | 9.4 (2.0 to 25.0) | 19.2 (6.6 to 39.4) | 22.9 (10.4 to 40.1) | 17.1 (6.6 to 33.6) | 21.9 (9.3 to 40.0) | 0 (0.0 to 14.2) | 8.3 (1.0 to 27.0) |
Duration of Response (DOR), computed for all treated participants with a best overall response (BOR) of complete response (CR) or partial response (PR), is defined as the time between the date of first response (CR or PR) and the date of first documented disease progression as determined by RECIST 1.1 or death due to any cause, whichever occurs first, ie., DOR = disease progression date/death date -first response date + 1. For participants who remain alive and have not progressed, DOR will be censored on the date of their last tumor assessment. CR= Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR= At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
| Weeks | Part 1-Arm A-Cohort 1: 1L CRC/BMS300BID + FOLFIRI | Part 1-Arm A-Cohort 2: 1L CRC/BMS600QD + FOLFIRI | Part 1-Arm B-Cohort 1: 1L PC/BMS300BID + GEM/NAB | Part 1-Arm B-Cohort 2: 1L PC/BMS600QD + GEM/NAB | Part 1-Arm C-Cohort 1: 2/3L CRC MSS/BMS300BID + NIVO | Part 1-Arm C-Cohort 2: 2/3L CRC MSS/BMS600QD + NIVO | Part 1-Arm C-Cohort 3: 2/3L CRC MSS/BMS300QD + NIVO | Part 1-Arm C-Cohort 4: 2/3L CRC MSS/BMS150QD + NIVO | Part 1-Arm C-Cohort 5: 2L PC/BMS300BID + NIVO | Part 1-Arm C-Cohort 6: 2L PC/BMS600QD + NIVO | Part 2-Arm A-Cohort 1a: 2L CRC/BMS300BID + FOLFIRI | Part 2-Arm A-Cohort 1b: 2L CRC/BMS150QD + FOLFIRI | Part 2-Arm A-Cohort 1C: 2L CRC/FOLFIRI | Part 2-Arm B-Cohort 3a: 1L PC/BMS300BID + GEM/NAB | Part 2-Arm B-Cohort 3b: 1L PC/BMS300BID + GEM/NAB + NIVO | Part 2-Arm B-Cohort 3C: 1L PC/GEM/NAB | Part 2-Arm C-Cohort 4: 2L PC/BMS300BID + NIVO | Part 2-Arm C-Cohort 5: 2/3L CRC MSS /BMS300BID + NIVO |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Duration of Response (DoR) | 159.00 (47.00 to NA) | NA (16.43 to NA) | — | NA (24.14 to NA) | — | — | — | — | — | — | 74.14 (32.14 to NA) | 56.57 (40.17 to NA) | 36.21 (16.14 to NA) | 32.14 (17.14 to 37.29) | 37.14 (14.14 to NA) | 20.57 (14.29 to 31.00) | — | NA (41.00 to NA) |
PFS rate is defined as the proportion of participants who were progression free at Week 24. PFS is defined as the time from first dose to the date of first objectively documented disease progression or death due to any cause, whichever occurs first. Progression is defined at least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 mm. Complete response (CR)= Disappearance of all target lesions. Pathological lymph nodes must have short axis reduction to \< 10 mm. Partial response (PR)= At least 30% decrease in sum of diameters of target lesions. Participants who died w/o prior progression were considered progressed on death date. Those alive and not progressed were censored on the last tumor assessment date. Those who started subsequent therapy without reported progression were censored at last tumor assessment prior to subsequent therapy. Those without post-baseline tumor assessment and alive were censored at first dose.
| Proportion of Participants | Part 1-Arm A-Cohort 1: 1L CRC/BMS300BID + FOLFIRI | Part 1-Arm A-Cohort 2: 1L CRC/BMS600QD + FOLFIRI | Part 1-Arm B-Cohort 1: 1L PC/BMS300BID + GEM/NAB | Part 1-Arm B-Cohort 2: 1L PC/BMS600QD + GEM/NAB | Part 1-Arm C-Cohort 1: 2/3L CRC MSS/BMS300BID + NIVO | Part 1-Arm C-Cohort 2: 2/3L CRC MSS/BMS600QD + NIVO | Part 1-Arm C-Cohort 3: 2/3L CRC MSS/BMS300QD + NIVO | Part 1-Arm C-Cohort 4: 2/3L CRC MSS/BMS150QD + NIVO | Part 1-Arm C-Cohort 5: 2L PC/BMS300BID + NIVO | Part 1-Arm C-Cohort 6: 2L PC/BMS600QD + NIVO | Part 2-Arm A-Cohort 1a: 2L CRC/BMS300BID + FOLFIRI | Part 2-Arm A-Cohort 1b: 2L CRC/BMS150QD + FOLFIRI | Part 2-Arm A-Cohort 1C: 2L CRC/FOLFIRI | Part 2-Arm B-Cohort 3a: 1L PC/BMS300BID + GEM/NAB | Part 2-Arm B-Cohort 3b: 1L PC/BMS300BID + GEM/NAB + NIVO | Part 2-Arm B-Cohort 3C: 1L PC/GEM/NAB | Part 2-Arm C-Cohort 4: 2L PC/BMS300BID + NIVO | Part 2-Arm C-Cohort 5: 2/3L CRC MSS /BMS300BID + NIVO |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Progression Free Survival (PFS) Rate at 24 Weeks | 0.778 (0.3648 to 0.9393) | NA (NA to NA) | 0.556 (0.2042 to 0.8045) | 0.800 (0.4087 to 0.9459) | — | — | — | NA (NA to NA) | — | — | 0.357 (0.1699 to 0.5490) | 0.536 (0.3372 to 0.6996) | 0.691 (0.4361 to 0.8478) | 0.535 (0.3512 to 0.6888) | 0.636 (0.4495 to 0.7746) | 0.467 (0.2779 to 0.6358) | — | NA (NA to NA) |
Cmax is defined as the maximum plasma concentration of the analytes at the prespecified timepoints.
| ng/mL | Part 1-Arm A-Cohort 1: 1L CRC/BMS300BID + FOLFIRI | Part 1-Arm A-Cohort 2: 1L CRC/BMS600QD + FOLFIRI | Part 1-Arm B-Cohort 1: 1L PC/BMS300BID + GEM/NAB | Part 1-Arm B-Cohort 2: 1L PC/BMS600QD + GEM/NAB | Part 1-Arm C-Cohort 1: 2/3L CRC MSS/BMS300BID + NIVO | Part 1-Arm C-Cohort 2: 2/3L CRC MSS/BMS600QD + NIVO | Part 1-Arm C-Cohort 3: 2/3L CRC MSS/BMS300QD + NIVO | Part 1-Arm C-Cohort 4: 2/3L CRC MSS/BMS150QD + NIVO | Part 1-Arm C-Cohort 5: 2L PC/BMS300BID + NIVO | Part 1-Arm C-Cohort 6: 2L PC/BMS600QD + NIVO | Part 2-Arm A-Cohort 1a: 2L CRC/BMS300BID + FOLFIRI | Part 2-Arm A-Cohort 1b: 2L CRC/BMS150QD + FOLFIRI | Part 2-Arm A-Cohort 1C: 2L CRC/FOLFIRI | Part 2-Arm B-Cohort 3a: 1L PC/BMS300BID + GEM/NAB | Part 2-Arm B-Cohort 3b: 1L PC/BMS300BID + GEM/NAB + NIVO | Part 2-Arm B-Cohort 3C: 1L PC/GEM/NAB | Part 2-Arm C-Cohort 4: 2L PC/BMS300BID + NIVO | Part 2-Arm C-Cohort 5: 2/3L CRC MSS /BMS300BID + NIVO |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| C0D1 - BMS-813160 | 620.4 ± 250.60 | 2204.1 ± 961.90 | 828.4 ± 458.03 | 2419.0 ± 1203.53 | 486.3 ± 137.69 | 1896.3 ± 1421.89 | 1179.1 ± 605.50 | 276.28 ± 141.915 | 1580.0 ± NA | 807.0 ± NA | — | — | — | — | — | — | — | — |
| C0D1 - BMS-939429 | 172.23 ± 103.837 | 435.6 ± 284.14 | 207.63 ± 142.559 | 545.7 ± 218.89 | 92.33 ± 50.015 | 539.1 ± 465.93 | 237.63 ± 188.286 | 54.82 ± 23.716 | 504.0 ± NA | 72.50 ± NA | — | — | — | — | — | — | — | — |
| C0D14 - BMS-813160 | 927.1 ± 513.88 | 4152.5 ± 2010.23 | 1060.3 ± 830.04 | 3274.0 ± 884.15 | 701.5 ± 284.59 | 1793.5 ± 1607.25 | 653.3 ± 298.08 | 80.00 ± 19.408 | 1370.0 ± NA | 1680.0 ± 961.67 | — | — | — | — | — | — | — | — |
| C0D14 - BMS-939429 | 317.90 ± 290.209 | 658.3 ± 143.17 | 409.63 ± 382.471 | 792.2 ± 503.92 | 183.08 ± 190.050 | 326.0 ± 241.83 | 165.83 ± 92.914 | 25.307 ± 16.6021 | 498.0 ± NA | 265.40 ± 235.608 | — | — | — | — | — | — | — | — |
| C2D1 - BMS-813160 | 1153.1 ± 617.97 | 3280.0 ± 777.82 | — | — | — | — | — | — | — | — | 903.9 ± 578.56 | 357.55 ± 264.384 | — | 796.2 ± 472.48 | — | — | — | — |
| C2D1 - BMS-939429 | 254.1 ± 140.73 | 571.0 ± 376.42 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Tmax is defined as the time in hours of the maximum observed plasma concentration
| Hours | Part 1-Arm A-Cohort 1: 1L CRC/BMS300BID + FOLFIRI | Part 1-Arm A-Cohort 2: 1L CRC/BMS600QD + FOLFIRI | Part 1-Arm B-Cohort 1: 1L PC/BMS300BID + GEM/NAB | Part 1-Arm B-Cohort 2: 1L PC/BMS600QD + GEM/NAB | Part 1-Arm C-Cohort 1: 2/3L CRC MSS/BMS300BID + NIVO | Part 1-Arm C-Cohort 2: 2/3L CRC MSS/BMS600QD + NIVO | Part 1-Arm C-Cohort 3: 2/3L CRC MSS/BMS300QD + NIVO | Part 1-Arm C-Cohort 4: 2/3L CRC MSS/BMS150QD + NIVO | Part 1-Arm C-Cohort 5: 2L PC/BMS300BID + NIVO | Part 1-Arm C-Cohort 6: 2L PC/BMS600QD + NIVO | Part 2-Arm A-Cohort 1a: 2L CRC/BMS300BID + FOLFIRI | Part 2-Arm A-Cohort 1b: 2L CRC/BMS150QD + FOLFIRI | Part 2-Arm A-Cohort 1C: 2L CRC/FOLFIRI | Part 2-Arm B-Cohort 3a: 1L PC/BMS300BID + GEM/NAB | Part 2-Arm B-Cohort 3b: 1L PC/BMS300BID + GEM/NAB + NIVO | Part 2-Arm B-Cohort 3C: 1L PC/GEM/NAB | Part 2-Arm C-Cohort 4: 2L PC/BMS300BID + NIVO | Part 2-Arm C-Cohort 5: 2/3L CRC MSS /BMS300BID + NIVO |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| C0D1 - BMS-813160 | 2.000 (0.50 to 4.00) | 0.500 (0.47 to 4.00) | 3.017 (2.00 to 4.02) | 2.492 (0.73 to 5.98) | 2.492 (0.52 to 11.92) | 2.983 (0.58 to 8.92) | 3.00 (0.50 to 6.00) | 1.992 (0.50 to 3.00) | 2.0 (2 to 2) | 3.950 (3.95 to 3.95) | — | — | — | — | — | — | — | — |
| C0D1 - BMS-939429 | 3.500 (0.50 to 6.25) | 1.000 (0.50 to 4.00) | 3.508 (1.00 to 11.98) | 3.000 (0.73 to 5.98) | 3.000 (1.0 to 11.92) | 2.083 (1.08 to 8.92) | 3.000 (1.00 to 6.00) | 2.000 (0.98 to 4.00) | 2.0 (2 to 2) | 1.950 (1.95 to 1.95) | — | — | — | — | — | — | — | — |
| C0D14 - BMS-813160 | 3.000 (0.55 to 3.03) | 1.825 (0.50 to 3.00) | 2.917 (0.92 to 15.70) | 2.983 (0.50 to 4.00) | 2.875 (0.50 to 3.00) | 2.0 (1 to 3) | 2.000 (1.00 to 3.02) | 1.00 (0.5 to 4.0) | 2.02 (2.02 to 2.02) | 2.542 (2.00 to 3.08) | — | — | — | — | — | — | — | — |
| C0D14 - BMS-939429 | 3.000 (0.98 to 4.00) | 1.825 (0.50 to 3.00) | 3.000 (1.08 to 15.70) | 2.983 (1.00 to 4.00) | 2.875 (1.17 to 3.00) | 2.492 (1.98 to 3.00) | 3.000 (1.00 to 4.02) | 1.0 (1 to 6) | 2.02 (2.02 to 2.02) | 3.117 (2.00 to 4.23) | — | — | — | — | — | — | — | — |
| C2D1 - BMS-813160 | 3.000 (0.98 to 4.23) | 1.000 (0.47 to 4.03) | — | — | — | — | — | — | — | — | 2.033 (0.50 to 14.10) | 2.067 (0.50 to 8.10) | — | 3.992 (0.50 to 16.17) | — | — | — | — |
| C2D1 - BMS-939429 | 3.000 (2.00 to 4.23) | 1.000 (0.97 to 4.03) | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Ctrough is defined as the concentration reached by a drug immediately before the next dose is administered
| ng/mL | Part 1-Arm A-Cohort 1: 1L CRC/BMS300BID + FOLFIRI | Part 1-Arm A-Cohort 2: 1L CRC/BMS600QD + FOLFIRI | Part 1-Arm B-Cohort 1: 1L PC/BMS300BID + GEM/NAB | Part 1-Arm B-Cohort 2: 1L PC/BMS600QD + GEM/NAB | Part 1-Arm C-Cohort 1: 2/3L CRC MSS/BMS300BID + NIVO | Part 1-Arm C-Cohort 2: 2/3L CRC MSS/BMS600QD + NIVO | Part 1-Arm C-Cohort 3: 2/3L CRC MSS/BMS300QD + NIVO | Part 1-Arm C-Cohort 4: 2/3L CRC MSS/BMS150QD + NIVO | Part 1-Arm C-Cohort 5: 2L PC/BMS300BID + NIVO | Part 1-Arm C-Cohort 6: 2L PC/BMS600QD + NIVO | Part 2-Arm A-Cohort 1a: 2L CRC/BMS300BID + FOLFIRI | Part 2-Arm A-Cohort 1b: 2L CRC/BMS150QD + FOLFIRI | Part 2-Arm A-Cohort 1C: 2L CRC/FOLFIRI | Part 2-Arm B-Cohort 3a: 1L PC/BMS300BID + GEM/NAB | Part 2-Arm B-Cohort 3b: 1L PC/BMS300BID + GEM/NAB + NIVO | Part 2-Arm B-Cohort 3C: 1L PC/GEM/NAB | Part 2-Arm C-Cohort 4: 2L PC/BMS300BID + NIVO | Part 2-Arm C-Cohort 5: 2/3L CRC MSS /BMS300BID + NIVO |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| C0D1 - BMS-813160 | 283.70 ± 207.784 | 84.30 ± 46.169 | 292.0 ± 154.31 | 74.05 ± 72.127 | 157.28 ± 92.311 | 137.0 ± NA | 57.10 ± 54.871 | 5.485 ± 2.4395 | 77.40 ± NA | 154.05 ± 139.936 | — | — | — | — | — | — | — | — |
| C5D1 - BMS-813160 | 268.80 ± 216.882 | 129.40 ± 89.944 | 176.0 ± NA | 15.30 ± NA | 323.0 ± NA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| C0D1 - BMS-939429 | 172.63 ± 264.187 | 31.40 ± 10.689 | 180.88 ± 195.959 | 72.95 ± 55.542 | 47.60 ± 10.412 | 31.50 ± NA | 63.45 ± 60.175 | 4.950 ± 2.3052 | 90.30 ± NA | 71.65 ± 55.649 | — | — | — | — | — | — | — | — |
| C1D15 - BMS 939429 | — | — | — | — | — | — | — | — | — | — | 191.33 ± 84.266 | 24.106 ± 18.445 | 275.7 ± 164.34 | 116.04 ± 29.696 | 145.00 ± 99.293 | — | 283.0 ± NA | — |
| C5D1 - BMS-939429 | 55.78 ± 31.877 | 15.95 ± 4.172 | 155.0 ± NA | 10.50 ± NA | 65.20 ± NA | — | — | — | — | — | 186.21 ± 131.457 | 12.439 ± 6.9685 | 195.0 ± NA | 191.44 ± 113.725 | 222.65 ± 154.316 | — | — | 390.0 ± NA |
Area Under Curve (AUC) is defined as the area under the plot of plasma concentration of a drug versus time after dosage measured at 8 hours post-dose
| ug*h/mL | Part 1-Arm A-Cohort 1: 1L CRC/BMS300BID + FOLFIRI | Part 1-Arm A-Cohort 2: 1L CRC/BMS600QD + FOLFIRI | Part 1-Arm B-Cohort 1: 1L PC/BMS300BID + GEM/NAB | Part 1-Arm B-Cohort 2: 1L PC/BMS600QD + GEM/NAB | Part 1-Arm C-Cohort 1: 2/3L CRC MSS/BMS300BID + NIVO | Part 1-Arm C-Cohort 2: 2/3L CRC MSS/BMS600QD + NIVO | Part 1-Arm C-Cohort 3: 2/3L CRC MSS/BMS300QD + NIVO | Part 1-Arm C-Cohort 4: 2/3L CRC MSS/BMS150QD + NIVO | Part 1-Arm C-Cohort 5: 2L PC/BMS300BID + NIVO | Part 1-Arm C-Cohort 6: 2L PC/BMS600QD + NIVO | Part 2-Arm A-Cohort 1a: 2L CRC/BMS300BID + FOLFIRI | Part 2-Arm A-Cohort 1b: 2L CRC/BMS150QD + FOLFIRI | Part 2-Arm A-Cohort 1C: 2L CRC/FOLFIRI | Part 2-Arm B-Cohort 3a: 1L PC/BMS300BID + GEM/NAB | Part 2-Arm B-Cohort 3b: 1L PC/BMS300BID + GEM/NAB + NIVO | Part 2-Arm B-Cohort 3C: 1L PC/GEM/NAB | Part 2-Arm C-Cohort 4: 2L PC/BMS300BID + NIVO | Part 2-Arm C-Cohort 5: 2/3L CRC MSS /BMS300BID + NIVO |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| C0D1 - BMS-813160 | 2300.018 ± 976.4608 | 7069.265 ± 2452.4213 | 2725.390 ± 1365.3562 | 7884.381 ± 3968.4940 | 1534.932 ± 518.2172 | 6593.904 ± 3603.5286 | 3533.737 ± 1931.7752 | 878.051 ± 535.3197 | 4440.313 ± NA | 3656.713 ± NA | — | — | — | — | — | — | — | — |
| C0D1 - BMS-939429 | 652.848 ± 363.5925 | 1783.336 ± 856.0103 | 936.394 ± 826.5807 | 2302.092 ± 1023.3978 | 342.534 ± 157.1350 | 2147.888 ± 1415.6386 | 942.398 ± 620.1018 | 210.938 ± 106.5352 | 1919.228 ± NA | 411.410 ± NA | — | — | — | — | — | — | — | — |
| C2D1 - BMS-813160 | 5348.973 ± 2506.2558 | 11967.560 ± 4586.3823 | — | — | — | — | — | — | — | — | 4838.264 ± 2750.7756 | 1483.423 ± 1236.0374 | — | 3821.887 ± 2221.2474 | — | — | — | — |
| C2D1 - BMS-939429 | 1410.415 ± 837.4895 | 2403.182 ± 1144.3271 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Area Under Curve (AUC) is defined as the area under the plot of plasma concentration of a drug versus time after dosage measured at 8 hours post-dose
| ug*h/mL | Part 1-Arm A-Cohort 1: 1L CRC/BMS300BID + FOLFIRI | Part 1-Arm A-Cohort 2: 1L CRC/BMS600QD + FOLFIRI | Part 1-Arm B-Cohort 1: 1L PC/BMS300BID + GEM/NAB | Part 1-Arm B-Cohort 2: 1L PC/BMS600QD + GEM/NAB | Part 1-Arm C-Cohort 1: 2/3L CRC MSS/BMS300BID + NIVO | Part 1-Arm C-Cohort 2: 2/3L CRC MSS/BMS600QD + NIVO | Part 1-Arm C-Cohort 3: 2/3L CRC MSS/BMS300QD + NIVO | Part 1-Arm C-Cohort 4: 2/3L CRC MSS/BMS150QD + NIVO | Part 1-Arm C-Cohort 5: 2L PC/BMS300BID + NIVO | Part 1-Arm C-Cohort 6: 2L PC/BMS600QD + NIVO | Part 2-Arm A-Cohort 1a: 2L CRC/BMS300BID + FOLFIRI | Part 2-Arm A-Cohort 1b: 2L CRC/BMS150QD + FOLFIRI | Part 2-Arm A-Cohort 1C: 2L CRC/FOLFIRI | Part 2-Arm B-Cohort 3a: 1L PC/BMS300BID + GEM/NAB | Part 2-Arm B-Cohort 3b: 1L PC/BMS300BID + GEM/NAB + NIVO | Part 2-Arm B-Cohort 3C: 1L PC/GEM/NAB | Part 2-Arm C-Cohort 4: 2L PC/BMS300BID + NIVO | Part 2-Arm C-Cohort 5: 2/3L CRC MSS /BMS300BID + NIVO |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| C0D1 - BMS-813160 | — | 9383.385 ± 2842.8397 | — | 11726.669 ± 6439.1376 | — | 10447.179 ± 2995.9347 | 4829.881 ± 2696.4668 | 1275.314 ± 799.8262 | — | 7687.658 ± NA | — | — | — | — | — | — | — | — |
| C0D1 - BMS-939429 | — | 2638.062 ± 977.2502 | — | 3991.522 ± 1636.3573 | — | 3905.941 ± 1852.8415 | 1660.159 ± 991.0121 | 341.0396 ± 160.4425 | — | 940.294 ± NA | — | — | — | — | — | — | — | — |
| C2D1 - BMS-813160 | — | 17890.458 ± 9212.5646 | — | — | — | — | — | — | — | — | — | 2050.804 ± 997.6990 | — | — | — | — | — | — |
| C2D1 - BMS-939429 | — | 3958.779 ± 1632.3781 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
The total body clearance (CLT/F) is defined as the volume of plasma completely cleared of drug per unit time
| mL/min | Part 1-Arm A-Cohort 1: 1L CRC/BMS300BID + FOLFIRI | Part 1-Arm A-Cohort 2: 1L CRC/BMS600QD + FOLFIRI | Part 1-Arm B-Cohort 1: 1L PC/BMS300BID + GEM/NAB | Part 1-Arm B-Cohort 2: 1L PC/BMS600QD + GEM/NAB | Part 1-Arm C-Cohort 1: 2/3L CRC MSS/BMS300BID + NIVO | Part 1-Arm C-Cohort 2: 2/3L CRC MSS/BMS600QD + NIVO | Part 1-Arm C-Cohort 3: 2/3L CRC MSS/BMS300QD + NIVO | Part 1-Arm C-Cohort 4: 2/3L CRC MSS/BMS150QD + NIVO | Part 1-Arm C-Cohort 5: 2L PC/BMS300BID + NIVO | Part 1-Arm C-Cohort 6: 2L PC/BMS600QD + NIVO | Part 2-Arm A-Cohort 1a: 2L CRC/BMS300BID + FOLFIRI | Part 2-Arm A-Cohort 1b: 2L CRC/BMS150QD + FOLFIRI | Part 2-Arm A-Cohort 1C: 2L CRC/FOLFIRI | Part 2-Arm B-Cohort 3a: 1L PC/BMS300BID + GEM/NAB | Part 2-Arm B-Cohort 3b: 1L PC/BMS300BID + GEM/NAB + NIVO | Part 2-Arm B-Cohort 3C: 1L PC/GEM/NAB | Part 2-Arm C-Cohort 4: 2L PC/BMS300BID + NIVO | Part 2-Arm C-Cohort 5: 2/3L CRC MSS /BMS300BID + NIVO |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| C0D14 - BMS-813160 | 1163.173 ± 588.1385 | 744.746 ± 361.5390 | 1521.863 ± 1277.8075 | 826.468 ± 300.1738 | 1602.009 ± 1123.8919 | 961.379 ± 235.4622 | 1688.813 ± 1022.7160 | 4950.110 ± 781.0155 | 1135.947 ± NA | 1032.434 ± 850.2203 | — | — | — | — | — | — | — | — |
| C2D1 - BMS-813160 | 956.446 ± 596.7553 | 683.958 ± 322.7045 | — | — | — | — | — | — | — | — | 1115.087 ± 851.2513 | 1813.987 ± 1920.2627 | — | 1440.516 ± 733.5156 | — | — | — | — |
Renal clearance is defined as the rate at which the analytes were removed from the plasma by the kidneys.
| mL/min | Part 1-Arm A-Cohort 1: 1L CRC/BMS300BID + FOLFIRI | Part 1-Arm A-Cohort 2: 1L CRC/BMS600QD + FOLFIRI | Part 1-Arm B-Cohort 1: 1L PC/BMS300BID + GEM/NAB | Part 1-Arm B-Cohort 2: 1L PC/BMS600QD + GEM/NAB | Part 1-Arm C-Cohort 1: 2/3L CRC MSS/BMS300BID + NIVO | Part 1-Arm C-Cohort 2: 2/3L CRC MSS/BMS600QD + NIVO | Part 1-Arm C-Cohort 3: 2/3L CRC MSS/BMS300QD + NIVO | Part 1-Arm C-Cohort 4: 2/3L CRC MSS/BMS150QD + NIVO | Part 1-Arm C-Cohort 5: 2L PC/BMS300BID + NIVO | Part 1-Arm C-Cohort 6: 2L PC/BMS600QD + NIVO | Part 2-Arm A-Cohort 1a: 2L CRC/BMS300BID + FOLFIRI | Part 2-Arm A-Cohort 1b: 2L CRC/BMS150QD + FOLFIRI | Part 2-Arm A-Cohort 1C: 2L CRC/FOLFIRI | Part 2-Arm B-Cohort 3a: 1L PC/BMS300BID + GEM/NAB | Part 2-Arm B-Cohort 3b: 1L PC/BMS300BID + GEM/NAB + NIVO | Part 2-Arm B-Cohort 3C: 1L PC/GEM/NAB | Part 2-Arm C-Cohort 4: 2L PC/BMS300BID + NIVO | Part 2-Arm C-Cohort 5: 2/3L CRC MSS /BMS300BID + NIVO |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| C0D1 - BMS-813160 | 212.411 ± 191.8961 | 275.309 ± 277.2659 | 139.012 ± 107.2006 | 165.327 ± 77.8766 | 155.820 ± 119.3858 | 181.930 ± 9.1130 | 248.003 ± 82.6974 | 236.781 ± 62.8689 | — | — | — | — | — | — | — | — | — | — |
| C0D1 - BMS-939429 | 74.298 ± 44.8889 | 175.109 ± 187.5683 | 68.184 ± 52.1580 | 77.744 ± 34.8177 | 81.027 ± 65.1050 | 98.733 ± 6.2562 | 140.597 ± 41.7347 | 128.943 ± 26.7782 | — | 62.007 | — | — | — | — | — | — | — | — |
| C0D14 - BMS-813160 | 185.926 ± 56.5866 | 124.400 ± 52.1454 | 260.786 ± 120.8954 | 168.274 ± 72.7581 | 158.238 ± 82.5905 | 194.009 ± 50.1111 | 283.842 ± 109.4518 | 149.271 ± 72.0204 | — | 115.147 | — | — | — | — | — | — | — | — |
| C0D14 - BMS-939429 | 101.042 ± 27.5043 | 76.285 ± 30.5071 | 145.662 ± 73.3215 | 91.490 ± 43.8006 | 87.068 ± 43.9667 | 111.649 ± 32.4552 | — | — | — | — | — | — | — | — | — | — | — | — |
The number of participants who are anti-drug antibody positive. ADA-positive participant is a participant with at least 1 ADA-positive sample relative to baseline after initiation of the treatment. ADA-positive sample is in a participant who is baseline ADA negative or with an ADA titer to be at least 4-fold or greater than baseline positive titer.
| Participants | Part 1-Arm A-Cohort 1: 1L CRC/BMS300BID + FOLFIRI | Part 1-Arm A-Cohort 2: 1L CRC/BMS600QD + FOLFIRI | Part 1-Arm B-Cohort 1: 1L PC/BMS300BID + GEM/NAB | Part 1-Arm B-Cohort 2: 1L PC/BMS600QD + GEM/NAB | Part 1-Arm C-Cohort 1: 2/3L CRC MSS/BMS300BID + NIVO | Part 1-Arm C-Cohort 2: 2/3L CRC MSS/BMS600QD + NIVO | Part 1-Arm C-Cohort 3: 2/3L CRC MSS/BMS300QD + NIVO | Part 1-Arm C-Cohort 4: 2/3L CRC MSS/BMS150QD + NIVO | Part 1-Arm C-Cohort 5: 2L PC/BMS300BID + NIVO | Part 1-Arm C-Cohort 6: 2L PC/BMS600QD + NIVO | Part 2-Arm A-Cohort 1a: 2L CRC/BMS300BID + FOLFIRI | Part 2-Arm A-Cohort 1b: 2L CRC/BMS150QD + FOLFIRI | Part 2-Arm A-Cohort 1C: 2L CRC/FOLFIRI | Part 2-Arm B-Cohort 3a: 1L PC/BMS300BID + GEM/NAB | Part 2-Arm B-Cohort 3b: 1L PC/BMS300BID + GEM/NAB + NIVO | Part 2-Arm B-Cohort 3C: 1L PC/GEM/NAB | Part 2-Arm C-Cohort 4: 2L PC/BMS300BID + NIVO | Part 2-Arm C-Cohort 5: 2/3L CRC MSS /BMS300BID + NIVO |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants Who Were Anti-Drug Antibody (ADA) Positive | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Collected over Participants were assessed for all-cause mortality from their randomization to study completion, (up to approximately 5.5 years). SAEs and Other AEs were assessed from first dose to 100 days following last dose (up to approximately 3 years).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1-Arm A-Cohort 1: 1L CRC/BMS300BID + FOLFIR | 6/10 (60%) | 5/10 (50%) | 10/10 (100%) |
| Part 1-Arm A-Cohort 2: 1L CRC/BMS600QD + FOLFIRI | 6/8 (75%) | 5/8 (62.5%) | 8/8 (100%) |
| Part 1-Arm B-Cohort 1: 1L PC/BMS300BID + GEM/NAB | 8/10 (80%) | 5/10 (50%) | 9/10 (90%) |
| Part 1-Arm B-Cohort 2: 1L PC/BMS600QD + GEM/NAB | 8/11 (72.7%) | 7/11 (63.6%) | 11/11 (100%) |
| Part 1-Arm C-Cohort 1: 2/3L CRC MSS/BMS300BID + NIVO | 6/8 (75%) | 5/8 (62.5%) | 8/8 (100%) |
| Part 1-Arm C-Cohort 2: 2/3L CRC MSS/BMS600QD + NIVO | 6/7 (85.7%) | 6/7 (85.7%) | 7/7 (100%) |
| Part 1-Arm C-Cohort 3: 2/3L CRC MSS/BMS300QD + NIVO | 6/7 (85.7%) | 6/7 (85.7%) | 7/7 (100%) |
| Part 1-Arm C-Cohort 4: 2/3L CRC MSS/BMS150QD + NIVO | 7/11 (63.6%) | 6/11 (54.5%) | 10/11 (90.9%) |
| Part 1-Arm C-Cohort 5: 2L PC/BMS300BID + NIVO | 1/1 (100%) | 1/1 (100%) | 1/1 (100%) |
| Part 1-Arm C-Cohort 6: 2L PC/BMS600QD + NIVO | 2/2 (100%) | 2/2 (100%) | 2/2 (100%) |
| Part 2-Arm A-Cohort 1a: 2L CRC/BMS300BID + FOLFIRI | 26/32 (81.3%) | 12/32 (37.5%) | 32/32 (100%) |
| Part 2-Arm A-Cohort 1b: 2L CRC/BMS150QD + FOLFIRI | 28/32 (87.5%) | 12/32 (37.5%) | 31/32 (96.9%) |
| Part 2-Arm A-Cohort 1C: 2L CRC/FOLFIRI | 17/26 (65.4%) | 6/26 (23.1%) | 25/26 (96.2%) |
| Part 2-Arm B-Cohort 3a: 1L PC/BMS300BID + GEM/NAB | 33/35 (94.3%) | 24/35 (68.6%) | 35/35 (100%) |
| Part 2-Arm B-Cohort 3b: 1L PC/BMS300BID + GEM/NAB + NIVO | 34/35 (97.1%) | 22/35 (62.9%) | 34/35 (97.1%) |
| Part 2-Arm B-Cohort 3C: 1L PC/GEM/NAB | 26/32 (81.3%) | 15/32 (46.9%) | 31/32 (96.9%) |
| Part 2-Arm C-Cohort 4: 2L PC/BMS300BID + NIVO | 20/24 (83.3%) | 17/24 (70.8%) | 19/24 (79.2%) |
| Part 2-Arm C-Cohort 5: 2/3L CRC MSS /BMS300BID + NIVO | 25/33 (75.8%) | 19/33 (57.6%) | 30/33 (90.9%) |
| Event | Part 1-Arm A-Cohort 1: 1L CRC/BMS300BID + FOLFIR | Part 1-Arm A-Cohort 2: 1L CRC/BMS600QD + FOLFIRI | Part 1-Arm B-Cohort 1: 1L PC/BMS300BID + GEM/NAB | Part 1-Arm B-Cohort 2: 1L PC/BMS600QD + GEM/NAB | Part 1-Arm C-Cohort 1: 2/3L CRC MSS/BMS300BID + NIVO | Part 1-Arm C-Cohort 2: 2/3L CRC MSS/BMS600QD + NIVO | Part 1-Arm C-Cohort 3: 2/3L CRC MSS/BMS300QD + NIVO | Part 1-Arm C-Cohort 4: 2/3L CRC MSS/BMS150QD + NIVO | Part 1-Arm C-Cohort 5: 2L PC/BMS300BID + NIVO | Part 1-Arm C-Cohort 6: 2L PC/BMS600QD + NIVO | Part 2-Arm A-Cohort 1a: 2L CRC/BMS300BID + FOLFIRI | Part 2-Arm A-Cohort 1b: 2L CRC/BMS150QD + FOLFIRI | Part 2-Arm A-Cohort 1C: 2L CRC/FOLFIRI | Part 2-Arm B-Cohort 3a: 1L PC/BMS300BID + GEM/NAB | Part 2-Arm B-Cohort 3b: 1L PC/BMS300BID + GEM/NAB + NIVO | Part 2-Arm B-Cohort 3C: 1L PC/GEM/NAB | Part 2-Arm C-Cohort 4: 2L PC/BMS300BID + NIVO | Part 2-Arm C-Cohort 5: 2/3L CRC MSS /BMS300BID + NIVO |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Blood bilirubin increasedInvestigations | 0/10 | 0/8 | 0/10 | 0/11 | 0/8 | 0/7 | 1/7 | 1/11 | 1/1 | 0/2 | 1/32 | 0/32 | 0/26 | 0/35 | 0/35 | 0/32 | 0/24 | 1/33 |
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/10 | 0/8 | 0/10 | 0/11 | 0/8 | 3/7 | 5/7 | 4/11 | 1/1 | 2/2 | 1/32 | 0/32 | 0/26 | 0/35 | 2/35 | 1/32 | 7/24 | 8/33 |
| General physical health deteriorationGeneral disorders | 0/10 | 0/8 | 0/10 | 0/11 | 0/8 | 0/7 | 0/7 | 0/11 | 0/1 | 1/2 | 0/32 | 0/32 | 0/26 | 0/35 | 0/35 | 0/32 | 0/24 | 0/33 |
| Deep vein thrombosisVascular disorders | 0/10 | 0/8 | 0/10 | 0/11 | 0/8 | 0/7 | 0/7 | 0/11 | 0/1 | 1/2 | 0/32 | 1/32 | 0/26 | 1/35 | 0/35 | 0/32 | 2/24 | 0/33 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/10 | 0/8 | 2/10 | 0/11 | 1/8 | 0/7 | 0/7 | 0/11 | 0/1 | 0/2 | 0/32 | 0/32 | 0/26 | 1/35 | 2/35 | 1/32 | 1/24 | 0/33 |
| NauseaGastrointestinal disorders | 0/10 | 1/8 | 0/10 | 2/11 | 0/8 | 0/7 | 0/7 | 0/11 | 0/1 | 0/2 | 0/32 | 0/32 | 0/26 | 2/35 | 1/35 | 1/32 | 3/24 | 0/33 |
| PyrexiaGeneral disorders | 1/10 | 1/8 | 0/10 | 2/11 | 0/8 | 0/7 | 0/7 | 0/11 | 0/1 | 0/2 | 0/32 | 0/32 | 0/26 | 4/35 | 5/35 | 2/32 | 0/24 | 0/33 |
| SepsisInfections and infestations | 0/10 | 0/8 | 0/10 | 2/11 | 0/8 | 0/7 | 0/7 | 0/11 | 0/1 | 0/2 | 1/32 | 0/32 | 0/26 | 5/35 | 2/35 | 1/32 | 1/24 | 0/33 |
| RashSkin and subcutaneous tissue disorders | 0/10 | 0/8 | 0/10 | 2/11 | 0/8 | 0/7 | 0/7 | 0/11 | 0/1 | 0/2 | 0/32 | 0/32 | 0/26 | 0/35 | 0/35 | 0/32 | 0/24 | 0/33 |
| Abdominal painGastrointestinal disorders | 1/10 | 1/8 | 1/10 | 1/11 | 0/8 | 0/7 | 1/7 | 0/11 | 0/1 | 0/2 | 3/32 | 0/32 | 0/26 | 2/35 | 3/35 | 2/32 | 3/24 | 2/33 |
| Event | Part 1-Arm A-Cohort 1: 1L CRC/BMS300BID + FOLFIR | Part 1-Arm A-Cohort 2: 1L CRC/BMS600QD + FOLFIRI | Part 1-Arm B-Cohort 1: 1L PC/BMS300BID + GEM/NAB | Part 1-Arm B-Cohort 2: 1L PC/BMS600QD + GEM/NAB | Part 1-Arm C-Cohort 1: 2/3L CRC MSS/BMS300BID + NIVO | Part 1-Arm C-Cohort 2: 2/3L CRC MSS/BMS600QD + NIVO | Part 1-Arm C-Cohort 3: 2/3L CRC MSS/BMS300QD + NIVO | Part 1-Arm C-Cohort 4: 2/3L CRC MSS/BMS150QD + NIVO | Part 1-Arm C-Cohort 5: 2L PC/BMS300BID + NIVO | Part 1-Arm C-Cohort 6: 2L PC/BMS600QD + NIVO | Part 2-Arm A-Cohort 1a: 2L CRC/BMS300BID + FOLFIRI | Part 2-Arm A-Cohort 1b: 2L CRC/BMS150QD + FOLFIRI | Part 2-Arm A-Cohort 1C: 2L CRC/FOLFIRI | Part 2-Arm B-Cohort 3a: 1L PC/BMS300BID + GEM/NAB | Part 2-Arm B-Cohort 3b: 1L PC/BMS300BID + GEM/NAB + NIVO | Part 2-Arm B-Cohort 3C: 1L PC/GEM/NAB | Part 2-Arm C-Cohort 4: 2L PC/BMS300BID + NIVO | Part 2-Arm C-Cohort 5: 2/3L CRC MSS /BMS300BID + NIVO |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sinus tachycardiaCardiac disorders | 0/10 | 0/8 | 0/10 | 1/11 | 0/8 | 0/7 | 3/7 | 0/11 | 1/1 | 0/2 | 1/32 | 0/32 | 0/26 | 0/35 | 1/35 | 1/32 | 1/24 | 1/33 |
| Abdominal pain upperGastrointestinal disorders | 1/10 | 1/8 | 0/10 | 2/11 | 2/8 | 0/7 | 1/7 | 1/11 | 1/1 | 0/2 | 1/32 | 4/32 | 1/26 | 3/35 | 3/35 | 2/32 | 3/24 | 0/33 |
| DiarrhoeaGastrointestinal disorders | 7/10 | 4/8 | 3/10 | 2/11 | 3/8 | 1/7 | 3/7 | 3/11 | 1/1 | 0/2 | 13/32 | 14/32 | 15/26 | 15/35 | 19/35 | 13/32 | 6/24 | 8/33 |
| VomitingGastrointestinal disorders | 3/10 | 1/8 | 4/10 | 3/11 | 1/8 | 1/7 | 5/7 | 2/11 | 1/1 | 1/2 | 6/32 | 10/32 | 8/26 | 10/35 | 11/35 | 9/32 | 5/24 | 0/33 |
| Non-cardiac chest painGeneral disorders | 0/10 | 0/8 | 0/10 | 1/11 | 0/8 | 0/7 | 0/7 | 0/11 | 1/1 | 0/2 | 3/32 | 2/32 | 0/26 | 2/35 | 2/35 | 0/32 | 1/24 | 1/33 |
| Peripheral swellingGeneral disorders | 0/10 | 0/8 | 0/10 | 0/11 | 0/8 | 0/7 | 0/7 | 0/11 | 1/1 | 0/2 | 0/32 | 0/32 | 0/26 | 5/35 | 2/35 | 2/32 | 0/24 | 0/33 |
| Amylase increasedInvestigations | 2/10 | 1/8 | 0/10 | 1/11 | 1/8 | 0/7 | 0/7 | 1/11 | 1/1 | 0/2 | 2/32 | 0/32 | 2/26 | 3/35 | 1/35 | 1/32 | 0/24 | 2/33 |
| Lipase increasedInvestigations | 4/10 | 1/8 | 1/10 | 1/11 | 2/8 | 0/7 | 0/7 | 1/11 | 1/1 | 0/2 | 4/32 | 2/32 | 1/26 | 3/35 | 6/35 | 1/32 | 0/24 | 2/33 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/10 | 0/8 | 1/10 | 1/11 | 3/8 | 0/7 | 3/7 | 0/11 | 1/1 | 0/2 | 1/32 | 0/32 | 1/26 | 10/35 | 9/35 | 6/32 | 3/24 | 3/33 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 1/10 | 0/8 | 0/10 | 0/11 | 0/8 | 0/7 | 0/7 | 0/11 | 1/1 | 0/2 | 0/32 | 1/32 | 1/26 | 1/35 | 3/35 | 1/32 | 0/24 | 1/33 |
| Age, Continuous(Years) | Part 1-Arm A-Cohort 1: 1L CRC/BMS300BID + FOLFIRI | Part 1-Arm A-Cohort 2: 1L CRC/BMS600QD + FOLFIRI | Part 1-Arm B-Cohort 1: 1L PC/BMS300BID + GEM/NAB | Part 1-Arm B-Cohort 2: 1L PC/BMS600QD + GEM/NAB | Part 1-Arm C-Cohort 1: 2/3L CRC MSS/BMS300BID + NIVO | Part 1-Arm C-Cohort 2: 2/3L CRC MSS/BMS600QD + NIVO | Part 1-Arm C-Cohort 3: 2/3L CRC MSS/BMS300QD + NIVO | Part 1-Arm C-Cohort 4: 2/3L CRC MSS/BMS150QD + NIVO | Part 1-Arm C-Cohort 5: 2L PC/BMS300BID + NIVO | Part 1-Arm C-Cohort 6: 2L PC/BMS600QD + NIVO | Part 2-Arm A-Cohort 1a: 2L CRC/BMS300BID + FOLFIRI | Part 2-Arm A-Cohort 1b: 2L CRC/BMS150QD + FOLFIRI | Part 2-Arm A-Cohort 1C: 2L CRC/FOLFIRI | Part 2-Arm B-Cohort 3a: 1L PC/BMS300BID + GEM/NAB | Part 2-Arm B-Cohort 3b: 1L PC/BMS300BID + GEM/NAB + NIVO | Part 2-Arm B-Cohort 3C: 1L PC/GEM/NAB | Part 2-Arm C-Cohort 4: 2L PC/BMS300BID + NIVO | Part 2-Arm C-Cohort 5: 2/3L CRC MSS /BMS300BID + NIVO | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| All Cohorts except Part 2-Arm C-Cohort 5 | 65.6 (54 to 83) | 53.3 (28 to 66) | 64.1 (54 to 80) | 62.7 (51 to 80) | 59.5 (48 to 76) | 61.7 (52 to 66) | 45.1 (33 to 57) | 60.5 (42 to 77) | 61.0 (61 to 61) | 50.0 (49 to 51) | 55.0 (29 to 76) | 58.9 (30 to 83) | 57.9 (37 to 77) | 65.9 (46 to 76) | 65.3 (43 to 85) | 65.5 (49 to 84) | 63.9 (34 to 77) | — | 61.4 (28 to 85) |
| Part 2-Arm C-Cohort 5 only | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 55.0 (39 to 69) | 55.0 (39 to 69) |
| Sex: Female, Male(Participants) | Part 1-Arm A-Cohort 1: 1L CRC/BMS300BID + FOLFIRI | Part 1-Arm A-Cohort 2: 1L CRC/BMS600QD + FOLFIRI | Part 1-Arm B-Cohort 1: 1L PC/BMS300BID + GEM/NAB | Part 1-Arm B-Cohort 2: 1L PC/BMS600QD + GEM/NAB | Part 1-Arm C-Cohort 1: 2/3L CRC MSS/BMS300BID + NIVO | Part 1-Arm C-Cohort 2: 2/3L CRC MSS/BMS600QD + NIVO | Part 1-Arm C-Cohort 3: 2/3L CRC MSS/BMS300QD + NIVO | Part 1-Arm C-Cohort 4: 2/3L CRC MSS/BMS150QD + NIVO | Part 1-Arm C-Cohort 5: 2L PC/BMS300BID + NIVO | Part 1-Arm C-Cohort 6: 2L PC/BMS600QD + NIVO | Part 2-Arm A-Cohort 1a: 2L CRC/BMS300BID + FOLFIRI | Part 2-Arm A-Cohort 1b: 2L CRC/BMS150QD + FOLFIRI | Part 2-Arm A-Cohort 1C: 2L CRC/FOLFIRI | Part 2-Arm B-Cohort 3a: 1L PC/BMS300BID + GEM/NAB | Part 2-Arm B-Cohort 3b: 1L PC/BMS300BID + GEM/NAB + NIVO | Part 2-Arm B-Cohort 3C: 1L PC/GEM/NAB | Part 2-Arm C-Cohort 4: 2L PC/BMS300BID + NIVO | Part 2-Arm C-Cohort 5: 2/3L CRC MSS /BMS300BID + NIVO | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| All Cohorts except Part 2-Arm C-Cohort 5 — Female | 3 | 2 | 6 | 6 | 2 | 3 | 3 | 3 | 1 | 0 | 13 | 11 | 9 | 15 | 15 | 15 | 8 | — | 115 |
| All Cohorts except Part 2-Arm C-Cohort 5 — Male | 7 | 6 | 4 | 5 | 6 | 4 | 4 | 8 | 0 | 2 | 19 | 21 | 17 | 20 | 20 | 17 | 16 | — | 176 |
| Part 2-Arm C-Cohort 5 only — Female | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 18 | 18 |
| Part 2-Arm C-Cohort 5 only — Male | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 15 | 15 |
| Ethnicity (NIH/OMB)(Participants) | Part 1-Arm A-Cohort 1: 1L CRC/BMS300BID + FOLFIRI | Part 1-Arm A-Cohort 2: 1L CRC/BMS600QD + FOLFIRI | Part 1-Arm B-Cohort 1: 1L PC/BMS300BID + GEM/NAB | Part 1-Arm B-Cohort 2: 1L PC/BMS600QD + GEM/NAB | Part 1-Arm C-Cohort 1: 2/3L CRC MSS/BMS300BID + NIVO | Part 1-Arm C-Cohort 2: 2/3L CRC MSS/BMS600QD + NIVO | Part 1-Arm C-Cohort 3: 2/3L CRC MSS/BMS300QD + NIVO | Part 1-Arm C-Cohort 4: 2/3L CRC MSS/BMS150QD + NIVO | Part 1-Arm C-Cohort 5: 2L PC/BMS300BID + NIVO | Part 1-Arm C-Cohort 6: 2L PC/BMS600QD + NIVO | Part 2-Arm A-Cohort 1a: 2L CRC/BMS300BID + FOLFIRI | Part 2-Arm A-Cohort 1b: 2L CRC/BMS150QD + FOLFIRI | Part 2-Arm A-Cohort 1C: 2L CRC/FOLFIRI | Part 2-Arm B-Cohort 3a: 1L PC/BMS300BID + GEM/NAB | Part 2-Arm B-Cohort 3b: 1L PC/BMS300BID + GEM/NAB + NIVO | Part 2-Arm B-Cohort 3C: 1L PC/GEM/NAB | Part 2-Arm C-Cohort 4: 2L PC/BMS300BID + NIVO | Part 2-Arm C-Cohort 5: 2/3L CRC MSS /BMS300BID + NIVO | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| All Cohorts except Part 2-Arm C-Cohort 5 — Hispanic or Latino | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 3 | 0 | 0 | 7 | 2 | 2 | 2 | 1 | 4 | 0 | — | 23 |
| All Cohorts except Part 2-Arm C-Cohort 5 — Not Hispanic or Latino | 8 | 5 | 8 | 9 | 8 | 7 | 6 | 7 | 0 | 2 | 21 | 26 | 17 | 28 | 30 | 24 | 21 | — | 227 |
| All Cohorts except Part 2-Arm C-Cohort 5 — Unknown or Not Reported | 2 | 3 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 0 | 4 | 4 | 7 | 5 | 4 | 4 | 3 | — | 41 |
| Part 2-Arm C-Cohort 5 only — Hispanic or Latino | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 4 | 4 |
| Part 2-Arm C-Cohort 5 only — Not Hispanic or Latino | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 23 | 23 |
| Part 2-Arm C-Cohort 5 only — Unknown or Not Reported | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 6 | 6 |
| Race (NIH/OMB)(Participants) | Part 1-Arm A-Cohort 1: 1L CRC/BMS300BID + FOLFIRI | Part 1-Arm A-Cohort 2: 1L CRC/BMS600QD + FOLFIRI | Part 1-Arm B-Cohort 1: 1L PC/BMS300BID + GEM/NAB | Part 1-Arm B-Cohort 2: 1L PC/BMS600QD + GEM/NAB | Part 1-Arm C-Cohort 1: 2/3L CRC MSS/BMS300BID + NIVO | Part 1-Arm C-Cohort 2: 2/3L CRC MSS/BMS600QD + NIVO | Part 1-Arm C-Cohort 3: 2/3L CRC MSS/BMS300QD + NIVO | Part 1-Arm C-Cohort 4: 2/3L CRC MSS/BMS150QD + NIVO | Part 1-Arm C-Cohort 5: 2L PC/BMS300BID + NIVO | Part 1-Arm C-Cohort 6: 2L PC/BMS600QD + NIVO | Part 2-Arm A-Cohort 1a: 2L CRC/BMS300BID + FOLFIRI | Part 2-Arm A-Cohort 1b: 2L CRC/BMS150QD + FOLFIRI | Part 2-Arm A-Cohort 1C: 2L CRC/FOLFIRI | Part 2-Arm B-Cohort 3a: 1L PC/BMS300BID + GEM/NAB | Part 2-Arm B-Cohort 3b: 1L PC/BMS300BID + GEM/NAB + NIVO | Part 2-Arm B-Cohort 3C: 1L PC/GEM/NAB | Part 2-Arm C-Cohort 4: 2L PC/BMS300BID + NIVO | Part 2-Arm C-Cohort 5: 2/3L CRC MSS /BMS300BID + NIVO | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| All Cohorts except Part 2-Arm C-Cohort 5 — American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | 0 |
| All Cohorts except Part 2-Arm C-Cohort 5 — Asian | 1 | 3 | 0 | 0 | 0 | 1 | 0 | 2 | 0 | 0 | 2 | 2 | 1 | 2 | 1 | 1 | 1 | — | 17 |
| All Cohorts except Part 2-Arm C-Cohort 5 — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | 0 |
| All Cohorts except Part 2-Arm C-Cohort 5 — Black or African American | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 3 | 2 | 0 | 0 | 2 | 0 | — | 10 |
| All Cohorts except Part 2-Arm C-Cohort 5 — White | 8 | 4 | 10 | 11 | 8 | 5 | 7 | 7 | 1 | 2 | 28 | 26 | 22 | 32 | 34 | 27 | 22 | — | 254 |
| All Cohorts except Part 2-Arm C-Cohort 5 — More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | 0 |
| All Cohorts except Part 2-Arm C-Cohort 5 — Unknown or Not Reported | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 2 | 1 | — | 10 |
| Part 2-Arm C-Cohort 5 only — American Indian or Alaska Native | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 0 | 0 |
| Part 2-Arm C-Cohort 5 only — Asian | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 1 | 1 |
| Part 2-Arm C-Cohort 5 only — Native Hawaiian or Other Pacific Islander | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 0 | 0 |
| Part 2-Arm C-Cohort 5 only — Black or African American | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 3 | 3 |
| Part 2-Arm C-Cohort 5 only — White | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 28 | 28 |
| Part 2-Arm C-Cohort 5 only — More than one race | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 0 | 0 |
| Part 2-Arm C-Cohort 5 only — Unknown or Not Reported | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Aug 2017 to primary completion in Apr 2023, 67 months.
Results were first posted in Oct 2025, 2 years 6 months after primary completion.
Of 158 industry-sponsored phase 1/2 interventional studies under Colorectal Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 82. This study's 67 months is above that.
Counting every sponsor, half of 260 studies reached it within 59 months; a quarter within 36 and three quarters within 87.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: BMS-813160 · Albumin-Bound Paclitaxel · Gemcitabine · Fluorouracil · Leucovorin · Irinotecan